Tarsus Pharmaceuticals, Inc. TARS Long-Term Debt
Long-Term Debt at other companies
Other financials
Where this comes from
Reported directly by Tarsus Pharmaceuticals, Inc. in its filing.
Tagged under the XBRL concept us-gaap:LongTermDebtNoncurrent.
The official record: Tarsus Pharmaceuticals, Inc.’s 10-Q, filed May 6, 2026, on SEC EDGAR. View the filing →
Ask your AI about Tarsus Pharmaceuticals, Inc.'s long-term debt.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Tarsus Pharmaceuticals, Inc.'s long-term debt?
- Tarsus Pharmaceuticals, Inc. (TARS) reported long-term debt of $72.6M in Q1 2026.
- How has Tarsus Pharmaceuticals, Inc.'s long-term debt changed year-over-year?
- Tarsus Pharmaceuticals, Inc.'s long-term debt increased by 0.9% year-over-year, from $71.98M to $72.6M.
- What does long-term debt mean?
- Bonds, term loans, notes payable, and other borrowings with maturities beyond one year — the primary long-term financing source.